SAN DIEGO and CALGARY, AB - Oncolytics Biotech Inc. (NASDAQ: NASDAQ:ONCY) (TSX: ONC), a biotechnology firm focused on immunotherapy for cancer, has received a notification from the Nasdaq regarding ...
Potential delays in clinical trials may result in extended timelines for new drug approvals, and a sudden reduction in ...
All high schools, including Elliot Alternative, offer the design, visual and media arts pathway. Davis, Downey, Gregori and ...
Cornerstone Research recently issued its 2024 Year in Review report examining recent trends in securities class action filings. For the second year ...
Operator: Thank you for standing by, and welcome to the Origin Agritech Fiscal Year 2024 Conference Call. Please note that, today ...
Hosted on MSN21h
Leerink Partners Upgrades Genmab A (GMAB)Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform to Outperform. Analyst Price Forecast Suggests 558.90% Upside As of ...
Stock analysts at Leerink Partnrs reduced their FY2024 EPS estimates for shares of United Therapeutics in a research note issued on Tuesday, February 11th. Leerink Partnrs analyst R. Ruiz now expects ...
Madison Sustainable Equity Fund stated the following regarding Danaher Corporation (NYSE:DHR) in its Q3 2024 investor letter: ...
Sam Finn, a senior research associate at Zymo Research working with the Oncology Diagnostic Team, helped to host this interactive game booth at the “BioFestival” on Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback